Filing Flows › Alpha Teknova (TKNO) › Q3 2026 › vs Q2 2026
Alpha Teknova (TKNO) Q3 2026 vs Q2 2026 (quarter over quarter)
Alpha Teknova's revenue rose $519K (+4%) from $12.2M in Q2 2026 to $12.7M in Q3 2026. The biggest changes: Clinical Solutions +$740K (+30%); Lab Essentials −$150K (-2%); Other Product −$71K (-12%).
Alpha Teknova, Q3 2026: revenue $12.7M (+22% year over year), operating margin -25.2%, net loss $3.5M, operating cash flow −$1.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Lab Essentials | $9.0M | $9.2M | −$150K | -2% |
| Clinical Solutions | $3.2M | $2.4M | $740K | +30% |
| Other Product | $502K | $573K | −$71K | -12% |
| Revenue | $12.7M | $12.2M | $519K | +4% |
| Net loss | $3.5M | $3.2M | $320K | +10% |
| Costs & expenses | $16.2M | $15.4M | $839K | +5% |
| Operating costs | $15.9M | $15.1M | $835K | +6% |
| Interest & other, net | $250K | $250K | $0 | 0% |
| Income tax | $34K | $30K | $4K | +13% |
| Cost of revenue | $7.9M | $7.3M | $578K | +8% |
| Research & development | $581K | $554K | $27K | +5% |
| Sales & marketing | $2.3M | $2.1M | $226K | +11% |
| General & admin | $4.8M | $4.8M | $4K | +0.1% |
| Other operating costs | $287K | $287K | $0 | 0% |
| Operating cash sources | $3.5M | $3.2M | $320K | +10% |
| Depreciation & amortization | $1.6M | $1.6M | −$4K | -0.3% |
| Share-based compensation | $612K | $622K | −$10K | -2% |
| Working capital & other | $11K | $484K | −$473K | -98% |
| Cash used in operations | $1.3M | $471K | $807K | +171% |
| Net loss absorbed | $3.5M | $3.2M | $320K | +10% |
Questions
How much did Alpha Teknova's revenue grow quarter over quarter in Q3 2026?
Alpha Teknova's revenue rose $519K (+4%) from $12.2M in Q2 2026 to $12.7M in Q3 2026.
What drove Alpha Teknova's revenue change in Q3 2026?
Clinical Solutions +$740K (+30%); Lab Essentials −$150K (-2%); Other Product −$71K (-12%).